Clinical trial
An Open-Label, First in Human, Phase 1/2 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 In Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
NCT05463263 is registered in ClinicalTrials.gov with Step Pharma, SAS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, First in Human, Phase 1/2 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 In Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
- Lead sponsor
- Step Pharma, SAS
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- August 3, 2022
- Completion date
- December 31, 2026
- Enrollment
- 180 (estimated)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.